Optical fiber‐based in vivo quantification of growth factor receptors
dc.contributor.author | Thomas, Thommey P. | en_US |
dc.contributor.author | Chang, Yu‐chung | en_US |
dc.contributor.author | Ye, Jing Yong | en_US |
dc.contributor.author | Kotlyar, Alina | en_US |
dc.contributor.author | Cao, Zhengyi | en_US |
dc.contributor.author | Shukla, Rameshwer | en_US |
dc.contributor.author | Qin, Suyang | en_US |
dc.contributor.author | Norris, Theodore B. | en_US |
dc.contributor.author | Baker, James R. | en_US |
dc.date.accessioned | 2012-05-21T15:49:47Z | |
dc.date.available | 2013-06-11T19:15:53Z | en_US |
dc.date.issued | 2012-04-15 | en_US |
dc.identifier.citation | Thomas, Thommey P.; Chang, Yu‐chung ; Ye, Jing Yong; Kotlyar, Alina; Cao, Zhengyi; Shukla, Rameshwer; Qin, Suyang; Norris, Theodore B.; Baker, James R. (2012). "Optical fiberâ based in vivo quantification of growth factor receptors ." Cancer 118(8): 2148-2156. <http://hdl.handle.net/2027.42/91221> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/91221 | |
dc.description.abstract | BACKGROUND: Growth factor receptors such as epidermal growth factor receptor 1 and human epidermal growth receptor 2 (HER2) are overexpressed in certain cancer cells. Antibodies against these receptors (eg. cetuximab and transtuzumab [Herceptin]) have shown therapeutic value in cancer treatment. The existing methods for the quantification of these receptors in tumors involve immunohistochemistry or DNA quantification, both in extracted tissue samples. The goal of the study was to evaluate whether an optical fiber‐based technique can be used to quantify the expression of multiple growth factor receptors simultaneously. METHODS: The authors examined HER2 expression using the monoclonal antibody trastuzumab as a targeting ligand to test their system. They conjugated trastuzumab to 2 different Alexa Fluor dyes with different excitation and emission wavelengths. Two of the dye conjugates were subsequently injected intravenously into mice bearing HER2‐expressing subcutaneous tumors. An optical fiber was then inserted into the tumor through a 30‐gauge needle, and using a single laser beam as the excitation source, the fluorescence emitted by the 2 conjugates was identified and quantified by 2‐photon optical fiber fluorescence. RESULTS: The 2 conjugates bound to the HER2‐expressing tumor competitively in a receptor‐specific fashion, but they failed to bind to a similar cell tumor that did not express HER2. The concentration of the conjugate present in the tumor as determined by 2‐photon optical fiber fluorescence was shown to serve as an index of the HER2 expression levels. CONCLUSIONS: These studies offer a minimally invasive technique for the quantification of tumor receptors simultaneously. Cancer 2012;. © 2011 American Cancer Society. The paper describes the in vivo quantification of human epidermal growth receptor 2 using a minimally invasive 2‐photon optical fiber fluorescence detection technique. The proof of concept for the simultaneous in vivo quantification of multiple receptors is provided. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Double‐Clad Optical Fiber | en_US |
dc.subject.other | Herceptin | en_US |
dc.subject.other | HER2 | en_US |
dc.subject.other | Growth Factor Receptor Quantification | en_US |
dc.subject.other | Cancer Targeting | en_US |
dc.subject.other | 2‐Photon Excitation | en_US |
dc.title | Optical fiber‐based in vivo quantification of growth factor receptors | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Michigan Nanotechnology Institute for Medicine and Biological Sciences and Department of Internal Medicine, University of Michigan, 9220 MSRB III, Box 0648, Ann Arbor, MI 48109 | en_US |
dc.contributor.affiliationum | Center for Ultrafast Optical Science, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Michigan Nanotechnology Institute for Medicine and Biological Sciences, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Biomedical Engineering, University of Texas at San Antonio, San Antonio, Texas | en_US |
dc.contributor.affiliationother | Department of Electrical Engineering, National Changhua University of Education, Changhua, Taiwan | en_US |
dc.identifier.pmid | 22488668 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/91221/1/26487_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.26487 | en_US |
dc.identifier.source | Cancer | en_US |
dc.identifier.citedreference | Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007; 131: 18 ‐ 43. | en_US |
dc.identifier.citedreference | Slamon DJ, Leyland‐Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783 ‐ 792; comment 2001;345:995‐997. | en_US |
dc.identifier.citedreference | Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER‐2‐positive early breast cancer. Oncologist. 2006; 11 ( suppl 1 ): 4 ‐ 12. | en_US |
dc.identifier.citedreference | Lewis F, Jackson P, Lane S, Coast G, Hanby AM. Testing for HER2 in breast cancer. Histopathology. 2004; 45: 207 ‐ 217. | en_US |
dc.identifier.citedreference | Fiuza M. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Ther. 2009; 26 ( suppl 1 ): S9 ‐ S17. | en_US |
dc.identifier.citedreference | Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20: 1215 ‐ 1221; comment 1156‐1157, 4119; author reply 4120. | en_US |
dc.identifier.citedreference | Jones RL, Smith IE. Efficacy and safety of trastuzumab. Exp Opin Drug Safety. 2004; 3: 317 ‐ 327. | en_US |
dc.identifier.citedreference | Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2‐positive metastatic breast cancer administered as first‐line treatment: the M77001 study group. J Clin Oncol. 2005; 23: 4265 ‐ 4274; comment 4247‐4250. | en_US |
dc.identifier.citedreference | Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER‐2 3+ overexpressing and fluorescent in situ hybridization‐positive metastatic breast cancer: a multi‐institutional phase II trial. J Clin Oncol. 2004; 22: 1071 ‐ 1077. | en_US |
dc.identifier.citedreference | Rhodes A, Borthwick D, Sykes R, Al‐Sam S, Paradiso A. The use of cell line standards to reduce HER‐2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol. 2004; 122: 51 ‐ 60; comment 2005;123:314; author reply 314‐315. | en_US |
dc.identifier.citedreference | Allred DC, Swanson PE, Allred DC, Swanson PE. Testing for erbB‐2 by immunohistochemistry in breast cancer [comment]. Am J Clin Pathol. 2000; 113: 171 ‐ 175. | en_US |
dc.identifier.citedreference | Press MF, Hung G, Godolphin W, et al. Sensitivity of HER‐2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994; 54: 2771 ‐ 2777. | en_US |
dc.identifier.citedreference | Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006; 24: 3032 ‐ 3038. | en_US |
dc.identifier.citedreference | Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER‐2/neu status of breast cancers using the United States Food and Drug Administration‐approved scoring system. J Clin Oncol. 1999; 17: 1983 ‐ 1987; comment 3690‐3692. | en_US |
dc.identifier.citedreference | Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration‐approved antibody. J Clin Oncol. 1999; 17: 434; comment 1650, 2293‐2294. | en_US |
dc.identifier.citedreference | Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue‐based detection of the HER‐2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18: 3651 ‐ 3664; comment Adv Anat Pathol. 2002;9:338‐344. | en_US |
dc.identifier.citedreference | Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002; 94: 855 ‐ 857; comment 788‐789; 2003;95:628; author reply 628‐629. | en_US |
dc.identifier.citedreference | Paik S, Bryant J, Tan‐Chiu E, et al. Real‐world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002; 94: 852 ‐ 854. | en_US |
dc.identifier.citedreference | Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118 ‐ 145. | en_US |
dc.identifier.citedreference | Schmitt F. HER2+ breast cancer: how to evaluate? Adv Ther. 2009; 26 ( suppl 1 ): S1 ‐ S8. | en_US |
dc.identifier.citedreference | Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol. 2005; 36: 250 ‐ 261. | en_US |
dc.identifier.citedreference | Beatty BG, Bryant R, Wang W, et al. HER‐2/neu detection in fine‐needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004; 122: 246 ‐ 255. | en_US |
dc.identifier.citedreference | Schmitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place [comment]. Am J Clin Pathol. 2001; 116: 806 ‐ 810. | en_US |
dc.identifier.citedreference | Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER‐2/neu gene and protein. Mol Cel Proteomics. 2004; 3: 379 ‐ 398. | en_US |
dc.identifier.citedreference | Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER‐2 status: which test to use [comment]? J Pathol. 2003; 199: 411 ‐ 417. | en_US |
dc.identifier.citedreference | Gordon PB. Image‐directed fine needle aspiration biopsy in nonpalpable breast lesions. Clin Lab Med. 2005; 25: 655 ‐ 678. | en_US |
dc.identifier.citedreference | Pisano ED, Fajardo LL, Tsimikas J, et al. Rate of insufficient samples for fine‐needle aspiration for nonpalpable breast lesions in a multicenter clinical trial: the Radiologic Diagnostic Oncology Group 5 Study. The RDOG5 investigators. Cancer. 1998; 82: 679 ‐ 688. | en_US |
dc.identifier.citedreference | Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2‐positive early breast cancer. Clin Cancer Res. 2007; 13: 1198 ‐ 1207. | en_US |
dc.identifier.citedreference | Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res. 2010; 70: 3857 ‐ 3860. | en_US |
dc.identifier.citedreference | Thomas TP, Ye JY, Yang C‐S, et al. Tissue distribution and real‐time fluorescence measurement of a tumor‐targeted nanodevice by a 2 photon optical fiber fluorescence probe. Proc SPIE. 2006; 60950Q1 – 60950Q7. | en_US |
dc.identifier.citedreference | Thomas TP, Myaing MT, Ye JY, et al. Detection and analysis of tumor fluorescence using a 2‐photon optical fiber probe. Biophys J. 2004; 86: 3959 ‐ 3965. | en_US |
dc.identifier.citedreference | Thomas TP, Ye JY, Chang YC, et al. Investigation of tumor cell targeting of a dendrimer nanoparticle using a double‐ clad optical fiber probe. J Biomed Opt. 2008; 13: 014024‐1 ‐ 014024‐6. | en_US |
dc.identifier.citedreference | Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421: 756 ‐ 760. | en_US |
dc.identifier.citedreference | Dijkers EC, de Vries EG, Kosterink JG, Brouwers AH, Lub‐de Hooge MN. Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. Curr Pharm Des. 2008; 14: 3348 ‐ 3362. | en_US |
dc.identifier.citedreference | Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast. 2009; 18 ( suppl 3 ): S66 ‐ S73. | en_US |
dc.identifier.citedreference | Giamas G, Man YL, Hirner H, et al. Kinases as targets in the treatment of solid tumors. Cell Signal. 2010; 22: 984 ‐ 1002. | en_US |
dc.identifier.citedreference | Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010; 28: 3366 ‐ 3379. | en_US |
dc.identifier.citedreference | Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst. 2009; 101: 1306 ‐ 1307. | en_US |
dc.identifier.citedreference | Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther. 2010; 10: 711 ‐ 724. | en_US |
dc.identifier.citedreference | Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol. 2010; 74: 73 ‐ 78. | en_US |
dc.identifier.citedreference | Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez‐Perez RR. Vascular endothelial growth factor receptor‐2 in breast cancer. Biochim Biophys Acta. 2010; 1806: 108 ‐ 121. | en_US |
dc.identifier.citedreference | Maass T, Thieringer FR, Mann A, et al. Liver specific overexpression of platelet‐derived growth factor‐B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer. 2011; 128: 1259 ‐ 1268. | en_US |
dc.identifier.citedreference | Kong D, Wang Z, Sarkar SH, et al. Platelet‐derived growth factor‐D overexpression contributes to epithelial‐mesenchymal transition of PC3 prostate cancer cells. Stem Cells. 2008; 26: 1425 ‐ 1435. | en_US |
dc.identifier.citedreference | Zhang T, Sun HC, Xu Y, et al. Overexpression of platelet‐ derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res. 2005; 11 ( 24 pt 1 ): 8557 ‐ 8563. | en_US |
dc.identifier.citedreference | Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet‐derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005; 7: R788 ‐ R795. | en_US |
dc.identifier.citedreference | Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res. 2010; 70: 5199 ‐ 5202. | en_US |
dc.identifier.citedreference | Elbauomy Elsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007; 9: R23. | en_US |
dc.identifier.citedreference | Freier K, Schwaenen C, Sticht C, et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2007; 43: 60 ‐ 66. | en_US |
dc.identifier.citedreference | Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10: 116 ‐ 129. | en_US |
dc.identifier.citedreference | Cappuzzo F, Tallini G, Finocchiaro G, et al. Insulin‐like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non‐small‐cell lung cancer (NSCLC) patients. Ann Oncol. 2010; 21: 562 ‐ 567. | en_US |
dc.identifier.citedreference | Li R, Pourpak A, Morris SW. Inhibition of the insulin‐like growth factor‐1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 2009; 52: 4981 ‐ 5004. | en_US |
dc.identifier.citedreference | Mabuchi S, Morishige K, Kimura T. Use of monoclonal antibodies in the treatment of ovarian cancer. Curr Opin Obstet Gynecol. 2010; 22: 3 ‐ 8. | en_US |
dc.identifier.citedreference | Roskoski J Jr. The ErbB/HER receptor protein‐tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004; 319: 1 ‐ 11. | en_US |
dc.identifier.citedreference | Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist. 2003; 8: 5 ‐ 17. | en_US |
dc.identifier.citedreference | Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26: 6469 ‐ 6487. | en_US |
dc.identifier.citedreference | Piccart‐Gebhart MJ, Procter M, Leyland‐Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2‐positive breast cancer. N Engl J Med. 2005; 353: 1659 ‐ 1672; comment 2005;353:1652‐1654; 2005;353:1734‐1736; 2006;354:640‐644. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.